Highlights of the European Association of Nuclear Medicine Congress, Athens, Greece, 30 September to 4 October 2006

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 2, 2007, Pages 274-293

  McKillop, J H ^a   Martin Comin, J ^b   Knapp Jr , F F ^c   Britten, A J ^d  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c OAK RIDGE NATIONAL LABORATORY   (United States)

^d ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Diagnosis; Nuclear medicine; Physics; Radiochemistry; Therapy

Indexed keywords

ANNEXIN B1 TC 99M; ARGINYLGLYCYLASPARTIC ACID; BENZOTHIAZOLE F 18; CYCLOPHOSPHAMIDE; CYSTEINYLGLYCYLCYSTEINYLAMIDE TC 99M; DEXTRAN TC 99M; FLUOROCHOLINE F 18; FLUORODEOXYGLUCOSE F 18; IBRITUMOMAB TIUXETAN; IODINATED POPPYSEED OIL I 131; LEXIDRONAM SAMARIUM SM 153; LEXIDRONAM Y 90; LIPIODOL RE 188; LIPOCORTIN 5; METAHYDROXYEPHEDRINE C 11; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MITOXANTRONE; NITRATE; OCTREOTIDE; PACLITAXEL; PENTETREOTIDE IN 111; PERTECHNETIC ACID TC 99M; PIMONIDAZOLE; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; SAMARIUM 153; TETROFOSMIN TC 99M; TRASTUZUMAB; UNCLASSIFIED DRUG; YTTRIUM 90;

ALZHEIMER DISEASE; APOPTOSIS; BONE METASTASIS; BREAST CANCER; CANCER DIAGNOSIS; COLORECTAL CANCER; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DRUG EFFICACY; DRUG MEGADOSE; DRUG UPTAKE; EDUCATION PROGRAM; GLIOBLASTOMA; GREECE; HEART INFARCTION SIZE; HUMAN; HYPERTHERMIC THERAPY; HYPOXIA; ISCHEMIA; LIVER CELL CARCINOMA; LYMPHOMA; MEDICAL EDUCATION; MEDICAL RESEARCH; MEDICAL SOCIETY; MULTIDRUG RESISTANCE; NERVOUS SYSTEM TUMOR; NEUROENDOCRINE TUMOR; NONHUMAN; NUCLEAR MEDICINE; OSTEOARTHRITIS; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PYREXIA IDIOPATHICA; RADIATION PHYSICS; RADIOCHEMISTRY; SCIENCE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR; TUMOR DIAGNOSIS; UNSPECIFIED SIDE EFFECT;

CLINICAL TRIALS; DIAGNOSTIC IMAGING; NUCLEAR MEDICINE; RADIOTHERAPY;

EID: 33846423198     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-006-0327-8     Document Type: Conference Paper

References (84)

1. Limouris GS. From the atomon of Democritus to the therapeutic nuclear medicine of today. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S65-8.
2. 18F] FMISO autoradiography with immunohistochemistry in a series of human squamous cell carcinoma xenografts. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S96-7.
3. Strauss LG, Klippel S, Schoenleben K, Haberkorn U, Dimitrakopoulou- Strauss A. Accuracy of tumor detection based on quantitative PET data obtained in colorectal tumors. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S120.
4. Dimitrakopoulou-Strauss A, Hoffmann M, Uppenkamp M, Haberkorn U, Strauss LG. Impact of full kinetic analysis of FDG follow-up studies in patients with non-small-cell-lung-cancer (NSCLC) receiving platin-based chemotherapy for prediction of therapy outcome. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S199.
5. Strauss LG, Koczan D, Klippel S, Pan L, Burger C, Haberkorn U, et al. Impact of apoptosis on FDG kinetics. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S153.
6. 11C-HED) compared with I-123-mIBG SPECT/CT. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S97.
7. 18F) PET/CT. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S154.
8. Cascini GL, Oliviero F, Vigliotti ML, Frigeri F, Aloj L, Caraco C, et al. FDG uptake in untreated follicular lymphoma. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S84.
9. Giacomuzzi F, Alghriw EH, Bonutti F, Cecotti A, Casco M, Rocco M, et al. FDG-PET-CT in the evaluation of pulmonary nodules: our experience in 160 patients. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S108.
10. Esnault J, Kolesnikov-Gauthier H, Adenis A, Fournier C, Carpentier P. How FDG-PET impacts the management of patients with colorectal cancer? Preliminary results of a follow-up study on 341 patients. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S120.
11. 18F-FDG PET/CT in the evaluation of pancreatic lesions. Eur J Nucl Med Mol Imaging 2006;33 (Suppl 2):S166.
12. Shibata K, Uno K, Wu J, Ka W, Matsuo Y, Suzuki T. Assessment of colorectal occult cancer risk in patients with incidental focal colonic fluorodeoxyglucose uptake: correlation with serum tumor marker and fecal occult blood test, multivariate logistic regression analysis. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S120.
13. Fencl P, Belohlavek O, Jaruskova M, Skopalova M, Kantorova I, Simonova K. Diagnostic accuracy and prognostics value of 18FDG-PET/CT in patients with carcinoma of unknown primary. An analysis of 190 investigations. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S83.
14. Garcia JR, Simo M, Soler M, Perez G, Lopez S, Lomeña F. Diagnostic value of FDG-PET in paraneoplastic syndromes. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S84.
15. 18F]-fluorodeoxyglucose for the pathologic complete response of primary tumor in breast cancer patients treated by neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S167.
16. Plotkin M, Gneveckow U, Wust P, Jordan A, Meier-Hauff K, Denecke T, et al. Use of F-18 FET-PET for planning of thermotherapy using magnetic nanoparticles in patients with recurrent glioblastoma. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S94.
17. Takeuchi R, Sengoku T, Okada M, Hosono M, Ohta H, Matsumura K. Early cancer diagnosis in healthy population, an epidemiological dilemma. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S152-3.
18. Acampa W, Mainolfi C, Ferro A, Ricci F, Evangelista L, Petretta MP, et al. Comparison of prognostic value of Tc-99 m tetrofosmin single-photon emission computed tomography after nitrate administration-vs-metabolic imaging by positron emission tomography in patients with ischemic left ventricular dysfunction. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S185.
19. 18F-FDG PET. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S151-2.
20. Bleeker-Rovers P, Vos FJ, Mudde AH, Dofferhoff AS, de Geus-Oei L, Rijnders AJ, et al. FDG-PET in patients with fever of unknown origin: a prospective multi-center study. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S192.
21. Rocha C, Vieira F, Costa G, Albuquerque A, Freitas D, Silva F, et al. Impact of aditional radioiodine treatment in well differentiated thyroid carcinoma in patients with negative whole-body scan and high thyroglobulin level. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S330.
22. Abdelrazek SS, Rogowski F, Szumowski P, Zonenberg A, Parfienczyk A, Szelachowska M, et al. The outcome of radioiodine therapy in patient with subclinical hyperthyroidism. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S333.
23. Rogowski F, Abdelazek S, Sawicka A, Parfieñczyk A, Szumowski P. The influence of non-radioactive iodine-127 on the outcome of radioiodine therapy in hyperthyroidism therapy. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S161.
24. Voliotopoulos V, Antypas C, Pantelis E, Filou-Giougi A, Valais I, Stavraka-Kakavaki A. Radioidine kinetic after the administration of recombinant human TSH for thyroid cancer therapy. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S332.
25. Zouboulis P, Megas P, Apostolopoulos D, Mylonas S, Papandrianos N, Lambiris E, et al. Yttrium-90 radiochemical synovectomy in treating idiopathic osteoarthritis of the knee. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S146.
26. Balogh I, Nagy Z, Gál P, Bakos M, Hajdú Z, Pászto T, et al. Comparative analysis of the results of Y-90-EDTMP and Sm-153-EDTMP treatment of painful bone metastases (multicentric trial). Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S159.
27. 188Re-HDD/Lipiodol for hepatocellular carcinoma: our experience with the first 100 treatments. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S215.
28. Bernal P, Raoul J, Vidmar G, Sereegotov C, Sundram FX, Kumar A, et al. Intra-arterial rhenium-188 lipiodol in the treatment of hepatocellular carcinoma: results of an IAEA sponsored multi-national study. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S215.
29. 99mTc-pertechnetate scintigraphy demonstrates in vivo sodium-iodide symporter expression in cancer patients. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S281.
30. Sinkó M, Rajtar M, Cserni G, Boross G, Tekle Wolde E, Ambrózay É. Axillary recurrence in 292 breast cancer patients with negative sentinel node biopsy and no axillary dissection. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S272.
31. 99mTc-EDDA/HYNIC-octreotate in intraoperative detection of neuroendocrine tumours of gastrointestinal tract (GEP-NET). Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S122.
32. 99mTc-HYNIC-Annexin V in experimental tumor model. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S210.
33. Gomes CMF, Welling MM, Que I, Henriquez NV, van der Pluijm G, Romeo S, et al. Molecular imaging of multidrug resistance in an orthotopic model of osteosarcoma. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S209.
34. Storto G, Sorrentino AR, Pellegrino T, Liuzzi R, Petretta MP, Salvatore M, et al. Assessment of coronary vascular function by sestamibi imaging in patients with diabetes and normal coronary arteries. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S139.
35. Tanaka R, Nakamura T, Chiba S, Yamazaki J. Effects of reverse redistribution phenomenon on 99m-sestamibi for microcirculatory disorder in patients with complete atrioventricular block. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S232.
36. Matsumoto C, Morishima T, Hatano T, Takazawa K. Does reverse redistribution on stress thallium-201 spect after myocardial revascularization mean adverse outcome?. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S239.
37. Bosnjakovic V, Sobic-Saranovic D, Pavlovic S, Petrasinovic Z, Kozarevic N, Todorovic-Tirnanic M, et al. Gated SPECT myocardial imaging: severity of perfusion abnormalities and difference in ejection fraction in patients with ischemia and myocardial infarction. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S235.
38. Gaemperli O, Schepis T, Valenta I, Koepfli P, Namdar M, Siegrist PT, et al. Complementary role of SPECT myocardial perfusion imaging and CT coronary calcium scoring for the assessment of hemodynamically significant coronary artery lesions. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S129.
39. Manrique A, Bernard M, Dronne F, Vera P, Bauer F, Grollier G, et al. Prognostic value of sympathetic innervation, left and right ejection fraction and LV asynchrony in dilated cardiomyopathy. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S185.
40. Gerasimou G, Papanastasiou, Konidari-Dedousi E, Liaros G, Psarrakos K, Kosta V, et al. Sensitivity in the diagnosis of Alzheimer's disease using as criteria the insult of a) one and b) three of the cerebral lobes: a Tc-99m-HMPAO SPET study. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S296.
41. Píchová R, Bartoš A, Trojanova H, Kukal J, Lang O. Relation between brain perfusion SPECT and mini-mental state examination in Alzheimer's disease. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S295.
42. 125I]desfluoro-DAA1106. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S294.
43. Antke C, Nolting T, Haslinger B, Beu M, Arendt G, Müller HW. SPECT-imaging of the dopaminergic system in HIV-infected patients with cognitive/motor complex. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S134.
44. Harris B, Bailey D, Roach P, Bailey E, King G. Objective analysis of the V/Q relationship in pulmonary embolism diagnosis using SPECT scintigraphy. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S170.
45. Tunariu N, Gibbs S, Win Z, Gin-Sing W, Graham A, AL-Nahhas A. V/Q scans are more sensitive than CTPA in detecting chronic pulmonary thromboembolic disease as a cause of pulmonary hypertension. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S170.
46. Ak I, Demirel G, Gulbas Z. Mrd1, mpr and lpr in patients with untreated acute leukemia: correlation with tc-99m mibi scintigraphy. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S354.
47. Limouris GS, Rousopoulos K, Panayides CT, Sideras P, Lamprakos L, Kouvaris J, et al. Scintigraphic/radiographic correlative evaluation of painful foot in the detection of acrometastasis. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S363.
48. 90Y in thr treatment of lymphoma. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S173.
49. 90Y Zevalin therapy. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S388.
50. 177Lu, alpha emitters....). Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S223.
51. 90Yactivity: optimization of the procedure and reduction of the radiopharmacist radiation exposure. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S90.
52. Duatti A, Uccelli L, Pasquali M, Boschi A, Cazzola E, Bedeschi P, et al. A remote-controlled automatic system for the labeling of lipiodol with Re-188 in the treatment of hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S105.
53. Decristoforo C, Knopp R, Haubner R, Schwarz S, von Guggenberg E, Virgolini I. Fully automated synthesis of 68Ga-labelled peptides applying fractionated elution of a commercially available generator. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S162.
54. Kersemans V, Cornelissen B, Dick JE, Reilly RM. Indium-111 labeled anti-CD33 monoclonal antibodies (mAbs) modified with nuclear-localizing sequences (NLS) kill mitoxantrone-resistant HL-60 acute myelogenous leukemia (AML) cells. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S91.
55. 103mRh-labelled somatostatin analogues: candidates for targeted radiation therapy of small neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S149.
56. Dijkgraaf I, Frielink C, Kruytzer J, Oyen WJG, Liskamp R, Corstens FHM, et al. Tumor targeting with a monomeric, dimeric and tetrameric RGD peptide. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S150.
57. 99mTc-dextran-70 radiopharmaceutical in rat. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S303.
58. 18F]fluorophenyl)-1,3-benzothiazole. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S218.
59. 99mTc-Annexin B1. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S210.
60. 99mTc]CGC-labeled peptides as caspase substrates for apoptosis imaging. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S162.
61. 3]octreotate. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S375.
62. Mueller C, Schibli R, Schubiger AP, Krenning EP, de Jong M. Antifolates significantly reduce undesired kidney accumulation of tumour targeting radiofolates. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S127.
63. Schulz V, Römer W, Noemayr A, Hornegger J, Herzog H, Bautz W, et al. Effect of CT-based attenuation correction on uptake ratios in skeletal SPECT. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S89.
64. Birchall JD, Blackwell KR, Ganatra RH, Griffith K, Perkins AC, Smith RM. Application of CT attenuation correction on lesion detection in SPECT imaging. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S318.
65. Livieratos L, Adamson K, Fernandez R, Gerarghty M, Allen S. Evaluation of three commercial systems for attenuation correction in SPECT. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S137.
66. Bailey DL, Schembri G, HoShon I, Brown S, Roach PJ. Hybrid SPECT/CT scanning in routine practice: incremental improvement in accuracy and impact of attenuation correction. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S137.
67. Gorska-Chrzastek M, Bienkiewicz M, Kusmierek J. Diagnostic benefits of dual-modality integrated imaging system SPECT/ CT by hybrid camera Infinia Hawekey - own experiences. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S317-8.
68. Celler AM, Tang L, Hamarneh G, Cohen P. Co-registration of CT-SPECT images for tumor localization and dosimetry. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S137-8.
69. Ye H, Krol A, Feiglin DH, Lipson ED, Lee W. Improved HMPAO brain SPECT with fan-beam-collimator reconstruction using OSEM with a fully 3D system model. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S197.
70. Yokoi TN, Yoshioka K, Takahashi Y, Teraoka S, Shinohara H. Reduction of collimator dependency in CBF using iterative reconstruction algorithm incorporating detector response correction for SPET. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S324.
71. Celler AM, Shcherbinin S, Trummer M, Cohen P. An iterative dual-isotope method for simultaneous imaging of myocardial viability and perfusion. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S217.
72. Sureau FC, Comtat C, Reader AJ, Leroy C, Santiago-Ribeiro MJ, Trébossen R. Impact of reconstruction with improved system modeling on high spatial resolution parametric PET imaging of the brain. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S197.
73. Lamare F, Ledesma-Carbayo M, Kontaxakis G, Santos A, Jarritt P, Mawlawi O, et al. An iterative image reconstruction algorithm for 4D PET/CT incorporating respiratory motion correction. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S147.
74. Martin SJ, Hutton BF. Motion in cardiac PET/CT: quantification of artefacts caused by attenuation mis-registrations. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S148.
75. Seppänen MP, Komar G, Kotoneva E, Teräs M, Minn H. Comparison of 2D and 3D VUE Point reconstruction of PET images with different acquisition times in oncological patients. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S136-7.
76. Zabalza L, Marti-Climent JM, Prieto E, Gómez M, Lecumberrri P, Bustince H, et al. Image quality assessment of different iterative reconstructions on PET images: a phantom study. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S314.
77. Tsujikawa T, Okazawa H, Ohtsuka H, Morita N, Nishitani H. Evaluation of the count recovery coefficient of a whole-body PET/CT scanner in 3D mode image. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S313.
78. 18F-FDG PET imaging for differentiating malignant from benign lesions. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S153.
79. Mavi A, Cermik TF, Urhan M, Zhuang H, Alav A. FDG PET dual time point imaging in the differentiation of post biopsy inflammation and primary tumor. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S167.
80. Santos JAM, Ruiz I, Bastos AL, Ponte F. Impact of FDG-PET in the occupational whole-body dose received by several professional groups in a Nuclear Medicine Department. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S125.
81. Sera T, Csernay L, Gavaller H, Boda L, Szanto G, Kardos L, et al. Promotion of radiation protection in clinical nuclear cardiology. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S125.
82. 186Re-HEDP scans; variations in the results due to the reconstruction used. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S178.
83. Sjogreen K, Nickel M, Lindén O, Strand S. Pharmacokinetic parametric images of antibody distributions based on serial whole-body scintillation-camera images and blood activity data. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S172.
84. Papavasileiou P, Divoli A, Hatziioannou K, Flux GD. A generalized 4D image registration scheme for targeted radionuclide therapy dosimetry. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S170-1.